PROMOTING ACCESS TO AFRICAN RESEARCH

Nigerian Journal of Ophthalmology

Log in or Register to get access to full text downloads.

Remember me or Register



Does Niprisanฎ Retard the Evolution of Sickle Cell Retinopathy?

OE Babalola, C Wambebe, S Cousens

Abstract


Objective: To investigate the efficacy of Niprisan®, an antisickling agent, in the management of sickle cell retinopathy.


Methods: The study was designed as a phase IIb double-blind, placebo-controlled crossover trial. Eighty-eight patients aged between 5 and 36 years (mean 15.3 years) were randomized into 2 treatment groups. One group received Niprisan® at a dose of 12mg/kg per os per day and the other group a placebo in a similarly encapsulated form, for an initial period of six months. After a crossover without interval washout, the treatment was continued for a further six months. Ocular signs, including jaundice and corkscrew/comma sign in the anterior segment, and signs of non-proliferative, pre-proliferative and proliferative retinopathy in the posterior segment, were assessed with a view to identifying deteriorations within these parameters.


Results: A within-person analysis provided no evidence that Niprisan® reduced the risk of anterior segment deterioration (odds ratio = 0.91; 95% c.i. 0.35, 2.36; p=1.00). Thirteen individuals contributed to the posterior segment analysis, 3 of whom experienced deterioration whilst receiving Niprisan® (odds ratio = 0.30, 95% c.i. 0.05-1.17; p=0.09; Mcnemar chi2 = 3.17, p=0.05).


Conclusion: This study provides evidence that Niprisan® may reduce substantially the risk of posterior segment deterioration.




[Nig. J. Ophthalmology Vol.11(1) 2003: 34-41]



http://dx.doi.org/10.4314/njo.v11i1.11896
AJOL African Journals Online